ORG US POSTAGE PAID VAN NUYS, CA PERMIT # 659 NONPROFIT

CME Symposium 200st IN ASSOCIATION WITH THE WCIRDC



EARN

CME

ABIM-MOC **CREDITS** 

1.75

# Winning the Trifecta of Diabetes, **Heart Disease, and Kidney Disease**

CONTR

**Thursday December 7, 2023** 7:30pm – 9:15pm PST **Hilton Universal City Hotel** Los Angeles, California **DINNER WILL BE SERVED** 

This is a CME Symposium Supported by an Educational Grant from AstraZeneca Free for all 21<sup>st</sup> WCIRDC Attendees | Register Online: wcir.org/registration This CME Symposium will be available and FREE for ONE year following the meeting.

ACCREDITED

MEEF Provided By:

Register Online: www.heartindiabetes.com/registration

**★**PESI CME MOC

Administered By:





### WINNING THE TRIFECTA OF DIABETES, HEART DISEASE, AND KIDNEY DISEASE

CHAIRS: Muthiah Vaduganathan, MD, MPH • Yehuda Handelsman, MD

7:30 pm — 9:15	pm Dinner CME Symposium	Supported by AstraZeneca
7:30 pm	Introduction & Pre-CME Questions	5
	Muthiah Vaduganathan, MD, MPH	l.
7:40 pm	7:40 pm Early intervention in Diabetes addressing pathophysiology in preventing comorbidities	
	Vivian A. Fonseca, MD	
8:00 pm	SGLT2i effects across the spectrum of CKD and multiple Populations Peter Rossing, MD	
8:20 pm	n Impact of SGLT2i on HF Outcomes in Various Populations & the range of LVEF	
	Muthiah Vaduganathan, MD, MPH	ł
8:40 pm	Panel Discussion and Q&A: Changing the Trajectory of Heart Failure and CKD, Implementing Guidelines Directed Medical Therapy	
	Panel: Vivian A. Fonseca, MD · Ch	ristian W. Mende, MD
	Erin D. Michos, MD · Peter Rossin	g, MD • Muthiah Vaduganathan, MD
	Moderator: Yehuda Handelsman, I	MD
9:10 pm	Concluding Remarks & Post-CME	Questions
9:15 pm	Adjourn	

#### **Program Description**

This satellite symposium will explore the changing landscape of therapies for the trifecta of diabetes, HF, and CKD. The program will address gaps in physicians' knowledge of the interconnections between diabetes, CKD, and heart failure and how to comprehensively manage these conditions when anyone, two, or all three are present in the same patient. The program will also address the management of patients with heart failure and CKD with no diabetes.

#### **Learning Objectives**

Upon completion of this CME symposium, participants should be able to:

- Understand the impact of early therapeutic interventions on the pathophysiologic pathways underlying the development of CKD and HF in patients with diabetes.
- Review evidence supporting the use of SGLT2 inhibitors across a wide range of patient populations with CKD.
- Describe Guidelines directed to medical therapy for patients with heart failure.
- Implement medical therapy regimens for patients with comorbid diseases, including those with HF and CKD, with and without diabetes.

### Target Audience

This educational initiative is designed for cardiologists, endocrinologists, nephrologists, internists, family physicians, and other healthcare professionals interested in the epidemiology, pathophysiology, prevention, and treatment of people with Heart failure or Type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.

## FACULTY



Muthiah Vaduganathan, MD, Chair MPH, FACC, FHFA, Cardiologist and Clinical Trialist Brigham and Women's Hospital and Harvard Medical School Co-director, Center for Cardiometabolic Implementation Science Boston. Massachusetts



Vivian A. Fonseca, MD, FRCP Professor of Medicine and Pharmacology Assistant Dean for Clinical Research Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Medical Center New Orleans, Louisiana

Baltimore, Maryland

Yehuda Handelsman, MD, Chair FACP, FNLA, FASPC, FAHA, MACE

Medical Director & Principal Investigator The Metabolic Institute of America Chair Scientific Advisory Board DCMi- Diabetes CardioRenal & Metabolism Institute Chair & Program Director 21st WCIRDC Tarzana, California



Peter Rossing, MD, DMSc Professor Department of Clinical Medicine University of Copenhagen Steno Diabetes Center Copenhagen Herlev, Denmark



Erin D. Michos, MD MHS, FAHA, FACC, FASE, FASPC Director of Women Cardiovascular Health Research Associate Director of Preventive Cardiology Division of Cardiology Johns Hopkins University School of Medicine Co-Director, IMPACT Center at JHU Co-Editor in Chief American Journal of Preventive Cardiology



Christian W. Mende, MD FACP, FACN, FASN, FAHA Clinical Professor of Medicine University of California San Diego La Jolla, California

### **CME DINNER SYMPOSIUM**

This CME symposium is FREE for 21st WCIRDC attendees and will stay on-demand for ONE year following the meeting. Learn more: WCIR.ORG/CMEsymposium

> To register for the entire 21st WCIRDC meeting Please visit: wcir.org/registration

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PESI Inc., and Metabolic Endocrine Education Foundation (MEEF). PES Inc. is accredited by the ACCME to provide continuing medical education for physicians.

PESI, Inc., designated this live educational activity for a maximum of 1.75 AMA PRA Category 1 Credit(s).

Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information please contact: info@tmioa.com or 818 342 1889

This is a CME Program Supported by an Educational Grant from AstraZeneca